Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases
Conditions: Unresectable Colon Cancer Peritoneal Metastases; PMMR/Ras/BRAF Wild-type Intervention: Drug: Serplulimab Combined With FOLFIRI and Bevacizumab Sponsors: Second Affiliated Hospital, School of Medicine, Zhejiang University; Changxing People's Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Avastin | Cancer | Cancer & Oncology | Colon Cancer | Colorectal Cancer | Hospitals | Peritoneal Cancer | Research